RGD Reference Report - FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.

Authors: Dannewitz Prosseda, Svenja  Tian, Xuefei  Kuramoto, Kazuya  Boehm, Mario  Sudheendra, Deepti  Miyagawa, Kazuya  Zhang, Fan  Solow-Cordero, David  Saldivar, Joshua C  Austin, Eric D  Loyd, James E  Wheeler, Lisa  Andruska, Adam  Donato, Michele  Wang, Lingli  Huebner, Kay  Metzger, Ross J  Khatri, Purvesh  Spiekerkoetter, Edda 
Citation: Dannewitz Prosseda S, etal., Am J Respir Crit Care Med. 2019 Jan 1;199(1):83-98. doi: 10.1164/rccm.201712-2553OC.
RGD ID: 329349307
Pubmed: PMID:30107138   (View Abstract at PubMed)
PMCID: PMC6353016   (View Article at PubMed Central)
DOI: DOI:10.1164/rccm.201712-2553OC   (Journal Full-text)


RATIONALE: Pulmonary arterial hypertension (PAH) is characterized by progressive narrowing of pulmonary arteries, resulting in right heart failure and death. BMPR2 (bone morphogenetic protein receptor type 2) mutations account for most familial PAH forms whereas reduced BMPR2 is present in many idiopathic PAH forms, suggesting dysfunctional BMPR2 signaling to be a key feature of PAH. Modulating BMPR2 signaling is therapeutically promising, yet how BMPR2 is downregulated in PAH is unclear.
OBJECTIVES: We intended to identify and pharmaceutically target BMPR2 modifier genes to improve PAH.
METHODS: We combined siRNA high-throughput screening of >20,000 genes with a multicohort analysis of publicly available PAH RNA expression data to identify clinically relevant BMPR2 modifiers. After confirming gene dysregulation in tissue from patients with PAH, we determined the functional roles of BMPR2 modifiers in vitro and tested the repurposed drug enzastaurin for its propensity to improve experimental pulmonary hypertension (PH).
MEASUREMENTS AND MAIN RESULTS: We discovered FHIT (fragile histidine triad) as a novel BMPR2 modifier. BMPR2 and FHIT expression were reduced in patients with PAH. FHIT reductions were associated with endothelial and smooth muscle cell dysfunction, rescued by enzastaurin through a dual mechanism: upregulation of FHIT as well as miR17-5 repression. Fhit-/- mice had exaggerated hypoxic PH and failed to recover in normoxia. Enzastaurin reversed PH in the Sugen5416/hypoxia/normoxia rat model, by improving right ventricular systolic pressure, right ventricular hypertrophy, cardiac fibrosis, and vascular remodeling.
CONCLUSIONS: This study highlights the importance of the novel BMPR2 modifier FHIT in PH and the clinical value of the repurposed drug enzastaurin as a potential novel therapeutic strategy to improve PAH.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
FHITHumanPulmonary Arterial Hypertension  ISOFhit (Mus musculus) RGD 
FhitRatPulmonary Arterial Hypertension  ISOFhit (Mus musculus) RGD 
FhitMousePulmonary Arterial Hypertension  IMP  RGD 

Objects Annotated

Genes (Rattus norvegicus)
Fhit  (fragile histidine triad diadenosine triphosphatase)

Genes (Mus musculus)
Fhit  (fragile histidine triad gene)

Genes (Homo sapiens)
FHIT  (fragile histidine triad diadenosine triphosphatase)


Additional Information